Kenneth Blum is a well-known American Scientist recognized for his work related to Psychopharmacology and Psychiatric Genetics. He received a B. Sc. degree in Pharmaceutical Science from Columbia University (NYC); a Master’s in Medicine from New Jersey College of Medicine (Rutgers) and a PhD in Neuropharmacology from New York Medical College. He is the recipient of many honors and awards including the Marquis Who’s Who -Distinguished Top Professional to be featured in the Wall Street Journal. DR. Blum has published over 730 peer reviewed articles, book chapters and meeting abstracts with 17 books with over 17,000 citations and 185,000 reads worldwide. He has distinguished himself and is credited with the first genetic association of the Dopamine D2 receptor gene and severe alcoholism published in JAMA, 1990. He is considered by some to be the Father of Psychiatric Genetics.  In1995, Dr. Blum coined the term “Reward Deficiency Syndrome (RDS)” and developed the USA and Foreign patented “Genetic Addiction Risk Severity” (GARS) test. Dr. Blum has also developed patented Pro-dopamine regulators in USA and Europe. His overall patent portfolio consists of 100 patents worldwide. Dr. Blum is the Editor -in-Chief on a number of academic journals including Current Psychopharmacology, addiction psychiatry, and Theranostic and Pharmacological Sciences. He also serves as Associate editor for Frontiers in Psychiatry and Frontiers in Public Health both related to the section on substance use disorder. He serves on 23 peer reviewed journals and is regional editor for Current Pharmaceutical & Biotechnology. His work has been featured in all the major media outlets worldwide and in 1990 his work on genetics was in the top 25 most important discoveries in science by Discovery Magazine. He is the recipient of NIH grants and has been awarded Lifetime Achievements, distinguished Honorary Doctors of Humane Letters; Life-time Honorary Professor at ELTE Eötvös Loránd University, Hungary and Distinguished Honorary Professor at Adelson School of Medicine, Ariel University, Israel. Currently, besides faculty positions as adjunct professor (Western University, University of Vermont, Wright School of Medicine), he is the Executive Chairman and CEO of TranspliceGen Therapeutics, Inc. Stanford university credited him as top 2% of the World Best scientist list (2023). Most recently the International Research Awards on Neurology and Neuro Disorders awarded him the “Best Researcher Award 2023”.